Alzheimer's Disease: Another Target for Heparin Therapy
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is the leading cause of dementia and cognitive decline in the elderly. Brain tissue changes indicate that the two main proteins involved in AD are amyloid-β(A-β), which is associated with the formation of senile amyloid plaques, and tau, which is associated with the formation of neurofibrillary tangles. Although a central role for A-β in the pathogenesis of AD is indisputable, considerable evidence indicates that A-β production is not the sole culprit in AD pathology. AD is also accompanied by an inflammatory response that contributes to irreversible changes in neuronal viability and brain function, and accumulating evidence supports the pivotal role of complement and contact systems in its pathogenesis and progression. The complexity of AD pathology provides numerous potential targets for therapeutic interventions. Compounds that interact directly with A-β protein or interfere with its production and/or aggregation can reduce the inflammatory and neurotoxic effects of A-β, and heparin, a glycosaminoglycan mixture currently used in the prophylaxis and treatment of thrombosis, might be a candidate, as recent research has been extended to consider its nonanticoagulant properties, including its modulation of various proteases and anti-inflammatory activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Copper, iron and zinc in Alzheimer's disease senile plaques
Lovell, M. A., Robertson, J. D., Teesdale, W. J., Campbell, J. L., & Markesbery, W. R. (1998) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(98)00092-6 · Cited by 2,120
Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective
Tanzi, R. E., & Bertram, L. (2005) · Cell · doi:10.1016/j.cell.2005.02.008 · Cited by 1,849
Rapid induction of Alzheimer A beta amyloid formation by zinc
Bush, A., Pettingell, W., Multhaup, G., d Paradis, M., Vonsattel, J., Gusella, J., Beyreuther, K., Masters, C., & Tanzi, R. (1994) · Science · doi:10.1126/science.8073293 · Cited by 1,522 · cited 2×
“In 1994, Bush and Tanzi discovered for the first time that Aβ becomes amyloidogenic in reaction to stoichiometric amounts of Zn 2+ and Cu 2+ [111,112], and recently they coined “The Metal Hypothesis of AD”, which proposed that the interaction of Aβ with these two metals drives Aβ pathogenicity and downstream AD pathol…”
BackgroundApolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy
Bu, G. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2620 · Cited by 1,168
The amyloid hypothesis for Alzheimer’s disease: A critical reappraisal
Hardy, J. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06181.x · Cited by 814 · cited 1×
“However, although the Aβ cascade hypothesis is one of the prevalent theories[41], some researchers suggest that this accumulation may not be sufficient to cause cognitive impairment[42], but it is necessary to trigger a series of other events (including the up-regulation of inflammatory responses, tau processing, and…”
BackgroundapoE isoform–specific disruption of amyloid β peptide clearance from mouse brain
Deane, R., Sagare, A., Hamm, K., Parisi, M., Lane, S., Finn, M. B., Holtzman, D. M., & Zlokovic, B. V. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36663 · Cited by 771 · cited 1×
“showed that Aβ binding to ApoEε4 redirected the rapid clearance of unbound Aβ40 and Aβ42 from LDL receptor-related protein-1 (LRP1) to the VLDL receptor (VLDLR), which has a substantially slower endocytotic rate than LRP1 and slowly clears ApoEε4 and Aβ-ApoEε4 complexes[198].”
BackgroundEpisodic memory loss is related to hippocampal-mediated -amyloid deposition in elderly subjects
Mormino, E. C., Kluth, J. T., Madison, C. M., Rabinovici, G. D., Baker, S. L., Miller, B. L., Koeppe, R. A., Mathis, C. A., Weiner, M. W., Jagust, W. J., et al. (2009) · Brain · doi:10.1093/brain/awn320 · Cited by 684
Atwood, C. S., Scarpa, R. C., Huang, X., Moir, R. D., Jones, W. D., Fairlie, D. P., Tanzi, R. E., & Bush, A. I. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0751219.x · Cited by 641
Mechanisms of tau-induced neurodegeneration
Iqbal, K., Liu, F., Gong, C.-X., Alonso, A. D. C., & Grundke-Iqbal, I. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0486-3 · Cited by 628
Water-soluble Aβ(N-40, N-42) oligomers in normal and Alzheimer disease brains
Kuo, Y.-M., Emmerling, M. R., Vigo-Pelfrey, C., Kasunic, T. C., Kirkpatrick, J. B., Murdoch, G. H., Ball, M. J., & Roher, A. E. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.8.4077 · Cited by 618 · cited 1×
“The aggregation of these monomeric Aβ peptides into oligomeric forms is associated with conformational changes and neurotoxicity in AD[10,11,12], although it is still not known whether this aggregation and the deposition of the oligomers in plaques are steps in the same pathway[13].”
Background
Cited by
Kanekiyo, T., Zhang, J., Liu, Q., Liu, C.-C., Zhang, L., & Bu, G. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.5491-10.2011 · Cited by 212
“Heparin binds to several classes of extracellular proteins, including growth factors, matrix proteins, and apolipoproteins (Bergamaschini et al., 2009).”
BackgroundMalavaki, C. J., Theocharis, A. D., Lamari, F. N., Kanakis, I., Tsegenidis, T., Tzanakakis, G. N., & Karamanos, N. K. (2011) · Biomedical Chromatography · doi:10.1002/bmc.1536 · Cited by 34
“HP has also been proposed as a promising therapeutic agent for Alzheimer’s disease (AD) because of its multiple effects, including its potential competitive interactions with proteoglycans, vascular effects, interactions with serpins and anti-inflammatory activity (Bergamaschini et al., 2009).”
BackgroundApoE3 Christchurch and tau interaction as a protective mechanism against Alzheimer's disease
Perez‐Corredor, P., Arevalo‐Alquichire, S., Mazzarino, R. C., O'Hare, M., Muriel‐Torres, A. F., Vacano, G. N., Vanderleest, T. E., Miller, W. P., Pineda‐Lopez, L., Patel, S., et al. (2025) · Alzheimer's & Dementia · doi:10.1002/alz.70396 · Cited by 7
Metadata
- Authors
- Bergamaschini, L., Rossi, E., Vergani, C., & De Simoni, M. G.
- Venue
- The Scientific World JOURNAL
- Publisher
- Hindawi Limited
- Published
- 2009
- Volume
- 9
- Pages
- 891-908
- ISSN
- 1537-744X (ISSN-L)
- OpenAlex
- W2080529683
- Cited by
- 47
- References
- 40
- FWCI
- 1.57
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Alzheimer's Disease: Another Target for Heparin Therapy. https://app.cochat.ai/papers/10.1100/tsw.2009.100
- The paper
- Bergamaschini, L., Rossi, E., Vergani, C., & De Simoni, M. G. (2009). Alzheimer's Disease: Another Target for Heparin Therapy. The Scientific World JOURNAL. https://doi.org/10.1100/tsw.2009.100
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.